—
C+
C+ The full Closelook — membership. Open the C+ overview

Guardant Health Inc (GH) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Guardant Health Inc

GH in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Guardant Health develops blood and tissue tests that detect and monitor cancer, using DNA fragments shed by tumours into the bloodstream. Its main products profile tumour mutations for treatment choices, track cancer recurrence after treatment, and screen adults for colorectal cancer through a blood draw rather than a colonoscopy. It also sells software and data services that connect test results to clinical trials for biopharmaceutical customers. The company is based in Palo Alto and serves oncologists, hospitals and drug developers in the United States and abroad.
Where it sits in the stack
Guardant Health sits in our Healthcare sector, within Diagnostics & Research, rather than in a Closelook index sleeve; it carries no seat in our build-out indices.
Who it is priced against
The diary groups it with scored Healthcare names based in the United States, including Regeneron, Vertex, BeiGene and Veeva; Exact Sciences is the wider competitor the market names in liquid-biopsy diagnostics.
Why Closelook tracks it
It carries a Closelook score, with momentum the strongest of its modules and valuation the weakest; it holds no seat in our indices and the diary has not yet quoted it in an edition.
What the diary watches
Whether the colorectal screening test gains wider reimbursement and test volume, since that would shift the balance between its momentum and its valuation reading.

Guardant Health Inc (GH) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for GH, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Diagnostics & Research · US · 8 names with week and year-to-date

Peer group

Diagnostics & Research · US

This name carries no Closelook score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against GH on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 50/100 · S&P 500 fund at 49, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-18
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 97th percentile of the window, +4.9% over 20 sessions. Factor regime → 2026-09-18
  • Sovereign pressure Index 0.07 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-18

FAQ · from the current data · as of 2026-09-19

Quick answers

What is Guardant Health Inc (GH)?

Guardant Health Inc trades as GH on the US exchange (US) in the Closelook research universe, as of the registry build of 2026-09-19.

Is GH in a Closelook index?

Not currently — Guardant Health Inc is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-19.

Where does GH trade against its moving averages?

Uptrend stack intact: Trades +11.4% vs the 50-day and +49.1% vs the 200-day average, 2.3% below the 52-week high and +223.9% off the 52-week low. Computed from daily closes. As of 2026-09-18 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Guardant Health Inc do?

Guardant Health develops blood and tissue tests that detect and monitor cancer, using DNA fragments shed by tumours into the bloodstream. Its main products profile tumour mutations for treatment choices, track cancer recurrence after treatment, and screen adults for colorectal cancer through a blood draw rather than a colonoscopy. It also sells software and data services that connect test results to clinical trials for biopharmaceutical customers. The diary groups it with scored Healthcare names based in the United States, including Regeneron, Vertex, BeiGene and Veeva; Exact Sciences is the wider competitor the market names in liquid-biopsy diagnostics.

Where does Guardant Health Inc sit in the AI build-out?

Guardant Health sits in our Healthcare sector, within Diagnostics & Research, rather than in a Closelook index sleeve; it carries no seat in our build-out indices. It carries a Closelook score, with momentum the strongest of its modules and valuation the weakest; it holds no seat in our indices and the diary has not yet quoted it in an edition.

What does this page show?

A live price chart with SMA overlays and drawing tools for GH, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Diagnostics & Research. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.